XML 61 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]        
Revenues $ 5,604 $ 5,596 $ 16,570 $ 16,332
Revenues 5,604 5,596 16,570 16,332
U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 4,219 4,151 12,110 11,781
Europe        
Disaggregation of Revenue [Line Items]        
Revenues 871 975 2,908 3,116
Other International        
Disaggregation of Revenue [Line Items]        
Revenues 514 470 1,552 1,435
Atripla        
Disaggregation of Revenue [Line Items]        
Revenues 149 258 472 921
Atripla | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 132 221 387 723
Atripla | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 10 29 52 119
Atripla | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 7 8 33 79
Biktarvy        
Disaggregation of Revenue [Line Items]        
Revenues 1,259 386 3,168 606
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 1,106 375 2,868 593
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 108 11 229 13
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 45 0 71 0
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Revenues 93 139 331 528
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 40 61 126 210
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 45 67 179 279
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 8 11 26 39
Descovy        
Disaggregation of Revenue [Line Items]        
Revenues 363 406 1,063 1,170
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 256 310 735 895
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 63 81 200 234
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 44 15 128 41
Genvoya        
Disaggregation of Revenue [Line Items]        
Revenues 978 1,176 2,973 3,418
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 761 921 2,222 2,678
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 152 203 522 596
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 65 52 229 144
Odefsey        
Disaggregation of Revenue [Line Items]        
Revenues 436 423 1,220 1,150
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 317 323 865 905
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 111 95 328 230
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 8 5 27 15
Stribild        
Disaggregation of Revenue [Line Items]        
Revenues 94 146 298 507
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 63 111 208 388
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 18 20 60 83
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 13 15 30 36
Truvada        
Disaggregation of Revenue [Line Items]        
Revenues 721 757 2,045 2,174
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 688 665 1,896 1,821
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 14 62 88 245
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 19 30 61 108
Other HIV        
Disaggregation of Revenue [Line Items]        
Revenues 5 14 37 46
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 3 10 23 30
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 1 2 3 6
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 1 2 11 10
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Revenues 104 22 254 42
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 68 8 165 8
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 36 14 89 34
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
AmBisome        
Disaggregation of Revenue [Line Items]        
Revenues 99 102 297 312
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 9 9 27 40
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 57 59 174 170
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 33 34 96 102
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Revenues 124 311 542 990
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 54 185 257 649
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 14 38 63 116
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 56 88 222 225
Letairis        
Disaggregation of Revenue [Line Items]        
Revenues 121 241 522 689
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 121 241 522 689
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
Ranexa        
Disaggregation of Revenue [Line Items]        
Revenues 31 178 205 581
Ranexa | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 31 178 205 581
Ranexa | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
Ranexa | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Revenues 516 477 1,500 1,513
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 282 225 731 733
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 118 136 428 502
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 116 116 341 278
Vemlidy        
Disaggregation of Revenue [Line Items]        
Revenues 134 87 351 221
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 78 66 214 172
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 6 2 15 8
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 50 19 122 41
Viread        
Disaggregation of Revenue [Line Items]        
Revenues 57 70 204 249
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 7 17 28 40
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 15 10 57 72
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 35 43 119 137
Vosevi        
Disaggregation of Revenue [Line Items]        
Revenues 63 103 201 319
Vosevi | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 42 78 140 250
Vosevi | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 12 21 43 57
Vosevi | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 9 4 18 12
Yescarta        
Disaggregation of Revenue [Line Items]        
Revenues 118 75 334 183
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 86 75 275 183
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 32 0 59 0
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 0 0 0 0
Zydelig        
Disaggregation of Revenue [Line Items]        
Revenues 26 20 79 92
Zydelig | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 13 15 36 46
Zydelig | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 13 4 42 44
Zydelig | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 0 1 1 2
Other(3)        
Disaggregation of Revenue [Line Items]        
Revenues 25 64 227 285
Other(3) | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 42 37 119 93
Other(3) | Europe        
Disaggregation of Revenue [Line Items]        
Revenues (21) 19 96 75
Other(3) | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 4 8 12 117
Product sales        
Disaggregation of Revenue [Line Items]        
Revenues 5,516 5,455 16,323 15,996
Product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 4,199 4,131 12,049 11,727
Product sales | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 804 873 2,727 2,883
Product sales | Other International        
Disaggregation of Revenue [Line Items]        
Revenues 513 451 1,547 1,386
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Revenues 88 141 247 336
Revenues 88 141 247 336
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Revenues 20 20 61 54
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Revenues 67 102 181 233
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Revenues $ 1 $ 19 $ 5 $ 49